Annual Meeting Session Highlights Clinical Pearls in Medical Dermatology
A key session at the annual meeting will share practical advice and tools to better support you and your patients.
Study Finds Successful Switching Strategy for Patients with Psoriasis After Suboptimal Response
What can you do when a medication for psoriasis yields a suboptimal response? New data presented at the 2023 AAD Annual Meeting provides valuable insight on next steps for treatment.
New Data on Investigational Agent for HS Presented at Annual Meeting
Promising phase 2 data for LY3041658 released during the Late-breaking Research session at the 2023 annual meeting.
A Cautionary Tale of Treatment Resistance at Annual Meeting
Expert warns lack of proper diagnosis and complete and thorough treatment of onychomycosis can lead to an endemic issue.
Investigational Gene Therapy Expected to Improve QoL for Patients With DEB
Designed to address the underlying causes of DEB, the investigational topical gene therapy shows great promise to improve quality of life for patients with this rare disorder.
Dermatologist Talks About the ABCs of Wounds and HS Support at Annual Meeting
Expert insights on the latest issues in wounds as well as HS resources are shared at the annual meeting.
Ruxolitinib Cream’s Impact on Quality of Life for Patients With Atopic Dermatitis
Using pooled 52-week results from TRuE-AD1 and TRuE-AD2, investigators examined how the topical JAK1/JAK 2 inhibitor affects patient feelings of skin pain, discomfort, anxiety, and depression.
STRATUM Phase 3 Trial: More Data on Roflumilast Foam 0.3% for Seborrheic Dermatitis
After reporting initial data earlier this year, investigators presented a fuller analysis in a poster at the 2022 SDPA Annual Fall Dermatology Conference.
ECZTRA 6: Tralokinumab’s Effect on Quality of Life for Adolescents With Atopic Dermatitis
The greatest improvements in quality of life measures were seen in the 300 mg tralokinumab group.
2 Clarke Drive Cranbury, NJ 08512